Zwierzina H - Search Results

1

Implementing liquid biopsies into clinical decision making for cancer immunotherapy.

Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B. Quandt D, et al. Among authors: zwierzina h. Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. Oncotarget. 2017. PMID: 28501851 Free PMC article. Review.

2

3D-cultivation of NSCLC cell lines induce gene expression alterations of key cancer-associated pathways and mimic in-vivo conditions.

Gamerith G, Rainer J, Huber JM, Hackl H, Trajanoski Z, Koeck S, Lorenz E, Kern J, Kofler R, Kelm JM, Zwierzina H, Amann A. Gamerith G, et al. Among authors: zwierzina h. Oncotarget. 2017 Nov 6;8(68):112647-112661. doi: 10.18632/oncotarget.22636. eCollection 2017 Dec 22. Oncotarget. 2017. PMID: 29348853 Free PMC article.

3

Innovation in oncology clinical trial design.

Verweij J, Hendriks HR, Zwierzina H; Cancer Drug Development Forum. Verweij J, et al. Among authors: zwierzina h. Cancer Treat Rev. 2019 Mar;74:15-20. doi: 10.1016/j.ctrv.2019.01.001. Epub 2019 Jan 4. Cancer Treat Rev. 2019. PMID: 30665053 Review.

4

Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.

Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Håkansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll H, Siena S, Tabernero J, Van Cutsem E. Zwierzina H, et al. Curr Opin Mol Ther. 2010 Dec;12(6):703-11. Curr Opin Mol Ther. 2010. PMID: 21154162 Review.

5

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM. Butterfield LH, et al. Among authors: zwierzina h. J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81. J Transl Med. 2008. PMID: 19105846 Free PMC article.

6

The impact of metformin and salinomycin on transforming growth factor β-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines.

Koeck S, Amann A, Huber JM, Gamerith G, Hilbe W, Zwierzina H. Koeck S, et al. Among authors: zwierzina h. Oncol Lett. 2016 Apr;11(4):2946-2952. doi: 10.3892/ol.2016.4323. Epub 2016 Mar 9. Oncol Lett. 2016. PMID: 27073581 Free PMC article.

7

Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers.

Koeck S, Zwierzina M, Huber JM, Bitsche M, Lorenz E, Gamerith G, Dudas J, Kelm JM, Zwierzina H, Amann A. Koeck S, et al. Among authors: zwierzina m, zwierzina h. Immunobiology. 2016 May;221(5):604-17. doi: 10.1016/j.imbio.2015.12.010. Epub 2016 Feb 1. Immunobiology. 2016. PMID: 26876590

8

The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3⁺CD8⁺ tumor infiltrating lymphocyte subpopulations.

Koeck S, Kern J, Zwierzina M, Gamerith G, Lorenz E, Sopper S, Zwierzina H, Amann A. Koeck S, et al. Among authors: zwierzina h. Oncoimmunology. 2017 May 8;6(6):e1323617. doi: 10.1080/2162402X.2017.1323617. eCollection 2017. Oncoimmunology. 2017. PMID: 28680763 Free PMC article.

9

Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.

Gamerith G, Amann A, Schenk B, Auer T, Lentzen H, Mügge DO, Cima KM, Löffler-Ragg J, Hilbe W, Zwierzina H. Gamerith G, et al. Among authors: zwierzina h. Oncol Lett. 2017 Nov;14(5):5563-5568. doi: 10.3892/ol.2017.6861. Epub 2017 Aug 31. Oncol Lett. 2017. PMID: 29142605 Free PMC article.

10

Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.

Gamerith G, Auer T, Amann A, Putzer D, Schenk B, Kircher B, Hilbe W, Zwierzina H, Loeffler-Ragg J. Gamerith G, et al. Among authors: zwierzina h. Cancer Biol Ther. 2014 Mar 1;15(3):266-70. doi: 10.4161/cbt.27327. Epub 2013 Dec 18. Cancer Biol Ther. 2014. PMID: 24351336 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112 results

Search Page